What OrganaBio’s Excellos asset acquisition reveals about next-generation CDMO demand
Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.
Pharma & Biotech
Medical Devices & Diagnostics
Is Legacy’s vasectomy solution setting a new standard for post-procedure patient management?
Legacy’s new AUA-aligned vasectomy platform combines sperm banking and mail-in PVSA—find out how it could reshape male fertility care in the U.S.